Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer

This study has been completed.
Sponsor:
Collaborators:
Bristol-Myers Squibb
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Information provided by (Responsible Party):
Jennifer Chan, MD, MPH, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00130689
First received: August 15, 2005
Last updated: December 18, 2012
Last verified: December 2012